BLACKSTONE LIFE SCIENCES
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
BLACKSTONE LIFE SCIENCES
Status:
Active
Similar Organizations
BBH Capital Partners
The private-equity arm of New York
Oaktree Capital Management
Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Platform Ventures
Platform Ventures, a real estate private equity investment firm.
Rhone Capital
Rhone Capital is a private equity arm of Rhone Group.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-15 | Sanofi | Blackstone Life Sciences investment in Post-IPO Equity - Sanofi | 300 M EUR |
| 2021-08-10 | Harmony Biosciences | Blackstone Life Sciences investment in Post-IPO Equity - Harmony Biosciences | 30 M USD |
| 2020-11-19 | Imago BioSciences | Blackstone Life Sciences investment in Series C - Imago BioSciences | 80 M USD |
| 2020-10-06 | Talaris Therapeutics | Blackstone Life Sciences investment in Series B - Talaris Therapeutics | 115 M USD |
| 2020-07-28 | Praxis Precision Medicines | Blackstone Life Sciences investment in Series C - Praxis Precision Medicines | 110 M USD |
| 2020-07-01 | Annexon Biosciences | Blackstone Life Sciences investment in Series C - Annexon Biosciences | 100 M USD |
| 2020-06-15 | Medtronic | Blackstone Life Sciences investment in Post-IPO Equity - Medtronic | 337 M USD |
| 2020-06-11 | Reata Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Reata Pharmaceuticals | 350 M USD |
| 2020-04-13 | Alnylam Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Alnylam Pharmaceuticals | 250 M USD |